Overall rank by patents
#28,042
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Ascendis Pharma BONE Diseases A/s
USPTO PatentsView assignee record - 9 granted patents across 3 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
9
Total patents granted
3
CPC technology areas
9.6
Avg claims per patent
-
5-year filing velocity
The verdict
Ascendis holds 9 US patents across 3 technology areas, rank #28,042 of 50,000 tracked assignees.
- #28,042
- of 50,000 US assignees by volume
- Top 37%
- by Innovation Score (39.8/100)
- 9.6
- avg claims per patent
Portfolio overview
Ascendis Pharma BONE Diseases A/s has been granted 9 US utility patents between 2023 and 2025, placing Ascendis Pharma BONE Diseases A/s at rank #28,042 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Ascendis Pharma BONE Diseases A/s is one of the more focused assignees in the PatentsView dataset. By volume, Ascendis sits between ARTE (9 patents, rank #28,038) and Aspect AI Ltd. (9 patents, rank #28,046) - the closest US assignees by grant volume. The composite Innovation Score of 39.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Ascendis Pharma BONE Diseases A/s's 9.6 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Ascendis Pharma BONE Diseases A/s against peers pursuing similar technology classes.
Who files at Ascendis's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- ARTE
ARTE
9 patents
- Artio Medical
ARTIO MEDICAL, INC.
9 patents
- Arvos
ARVOS GmbH
9 patents
- Asahi Organic Che…
ASAHI ORGANIC CHEMICALS INDUSTRY CO., LTD.
9 patents
- Asclepius (Suzhou…
ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
9 patents
- Asgco Manufacturi…
ASGCO Manufacturing, Inc.
9 patents
- ASIA IC Mic-proce…
ASIA IC MIC-PROCESS, INC.
9 patents
- Aspect AI
ASPECT AI LTD.
9 patents
- Ascendis Pharma B… ◀
ASCENDIS PHARMA BONE DISEASES A/S
9 patents
What this shows Ascendis holds 9 patents at rank #28,042, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Ascendis
By rank, the assignees closest to #28,042 in granted patent volume.
- ARTE #28,038 · 9 patents
- Artio Medical, Inc. #28,039 · 9 patents
- Arvos Gmbh #28,040 · 9 patents
- Asahi Organic Chemicals Industry Co., Ltd. #28,041 · 9 patents
- Asclepius (suzhou) Technology Company Group Co., Ltd. #28,043 · 9 patents
- Asgco Manufacturing, Inc. #28,044 · 9 patents
- ASIA IC Mic-process, Inc. #28,045 · 9 patents
- Aspect AI Ltd. #28,046 · 9 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Ascendis's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Ascendis's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
40 Top 37% higher than 63% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 3 | 33.3% |
| 2024 | 3 | 33.3% |
| 2025 | 3 | 33.3% |
Which technologies does Ascendis Pharma BONE Diseases A/s patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Simple
Frequently Asked Questions
How many patents does Ascendis Pharma BONE Diseases A/s hold?
Ascendis Pharma BONE Diseases A/s holds 9 US granted patents filed between 2023 and 2025, spanning 3 technology areas.
What is Ascendis Pharma BONE Diseases A/s's Innovation Score?
Ascendis Pharma BONE Diseases A/s has an Innovation Score of 39.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Ascendis Pharma BONE Diseases A/s focus on?
Ascendis Pharma BONE Diseases A/s's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 9 patents. The company has filed patents in 3 CPC subclasses total.
Is Ascendis Pharma BONE Diseases A/s's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Ascendis Pharma BONE Diseases A/s.
What does claim depth mean for Ascendis Pharma BONE Diseases A/s's patents?
Ascendis Pharma BONE Diseases A/s's patents average 9.6 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Ascendis Pharma BONE Diseases A/s patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Ascendis's 9 grants land it in the top 37% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Ascendis ranks #28,042 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.